CA2283636A1 - Genes cibles pour medicaments specifiques d'alleles - Google Patents

Genes cibles pour medicaments specifiques d'alleles Download PDF

Info

Publication number
CA2283636A1
CA2283636A1 CA002283636A CA2283636A CA2283636A1 CA 2283636 A1 CA2283636 A1 CA 2283636A1 CA 002283636 A CA002283636 A CA 002283636A CA 2283636 A CA2283636 A CA 2283636A CA 2283636 A1 CA2283636 A1 CA 2283636A1
Authority
CA
Canada
Prior art keywords
gene
patient
inhibitor
allele
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002283636A
Other languages
English (en)
Inventor
David Housman
Fred D. Ledley
Vincent P. Stanton, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2283636A1 publication Critical patent/CA2283636A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des cibles génétiques utiles pour des thérapies antitumorales spécifiques d'allèles. La stratégie de tels traitements comporte les étapes consistant à: (1) identifier des allèles distincts de gènes codant pour des protéines essentielles à la vie ou à la croissance des cellules, et à la perte de l'un de ces allèles dans des cellules cancéreuses, due à la perte d'hétérozygotie (LOH); et (2) développer des inhibiteurs présentant une spécificité élevée pour l'allèle distinct restant du gène essentiel retenu par la cellule tumorale après LOH. Des catégories particulières de gènes cibles appropriés sont décrites, ainsi que des gènes servant d'exemples pour ces catégories, et des procédés d'utilisation de tels gènes cibles.
CA002283636A 1997-03-20 1998-03-19 Genes cibles pour medicaments specifiques d'alleles Abandoned CA2283636A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4105797P 1997-03-20 1997-03-20
US60/041,057 1997-03-20
PCT/US1998/005419 WO1998041648A2 (fr) 1997-03-20 1998-03-19 Genes cibles pour medicaments specifiques d'alleles

Publications (1)

Publication Number Publication Date
CA2283636A1 true CA2283636A1 (fr) 1998-09-24

Family

ID=21914484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283636A Abandoned CA2283636A1 (fr) 1997-03-20 1998-03-19 Genes cibles pour medicaments specifiques d'alleles

Country Status (4)

Country Link
EP (1) EP0973935A2 (fr)
AU (1) AU6764398A (fr)
CA (1) CA2283636A1 (fr)
WO (1) WO1998041648A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074902B1 (en) 1998-04-27 2006-07-11 Warf Wisconsin Alumni Research Foundation Antibody specific for a DNA repair protein
US7122343B1 (en) * 1998-04-27 2006-10-17 Wisconsin Alumni Research Foundation Methods to alter levels of a DNA repair protein
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US6309882B1 (en) 1999-09-10 2001-10-30 Isis Pharmaceuticals, Inc. Antisense inhibition of replication protein a p70 subunit
JP4871468B2 (ja) * 1999-09-14 2012-02-08 ザ スクリプス リサーチ インスティチュート 新規な細胞周期チェックポイント遺伝子およびそれがコードするタンパク質
JP2003521896A (ja) * 1999-11-15 2003-07-22 ユニバーシティ・オブ・サザン・カリフォルニア 治療応答を予測するためのゲノム多形現象
EP1238281A2 (fr) * 1999-12-01 2002-09-11 Ludwig Institute For Cancer Research Antigenes associes au cancer et utilisations correspondantes
US20030092601A1 (en) * 1999-12-07 2003-05-15 Hanan Polansky Microcompetition and human disease
GB0000995D0 (en) * 2000-01-18 2000-03-08 Zeneca Ltd Methods
WO2002021134A2 (fr) * 2000-09-08 2002-03-14 Eos Biotechnology, Inc. Nouveaux procedes permettant de diagnostiquer le cancer du sein, compositions et procedes de criblage pour modulateurs de cancer du sein
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
US7049059B2 (en) 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6956111B2 (en) 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
KR20060026052A (ko) 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
CA2553261C (fr) 2004-01-16 2014-03-18 Stefan Barth Immunokinases
EP1800695A1 (fr) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA conjugues
WO2007079128A1 (fr) 2005-12-30 2007-07-12 Ventana Medical Systems, Inc. Expression de na+/k+-atpase dans une dysplasie du col de l'uterus et un cancer du col de l'uterus
US7704967B2 (en) 2006-03-14 2010-04-27 University Of Maryland, Baltimore TFIIS and GDOWN1 as targets for cancer therapy
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
IN2014DN05803A (fr) * 2011-12-14 2015-05-15 Univ Texas
WO2013174859A1 (fr) * 2012-05-22 2013-11-28 Centre Leon Berard Procédés de criblage pour identifier des composés interférant avec coup-tfii (nr2f2) ou coup-tfi (nr2f1)
US9828641B2 (en) 2013-08-01 2017-11-28 The Regents Of The University Of California Systemic genotoxicity as blood marker for allergic inflammation
US10322164B2 (en) 2014-01-16 2019-06-18 Rowan University Modulation of cellular localization of cyclin C
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
US20210047696A1 (en) * 2018-03-28 2021-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2024223797A1 (fr) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Utilisation d'inhibiteurs de cyp3a4 pour le traitement d'infections par le virus de l'hépatite d (vhd)
CN120173770A (zh) * 2025-05-21 2025-06-20 南京工业大学 一种高产3'-脱氧腺苷的基因工程菌株及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491064A (en) * 1992-07-17 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services HTS-1 gene, a human tumor suppressor gene
EP0674705A4 (fr) * 1992-11-09 1997-11-26 Univ Jefferson Oligonucleotides antisens utilises pour inhiber l'expression de genes de collagene ayant subis une mutation et de type sauvage.
WO1995003335A1 (fr) * 1993-07-26 1995-02-02 K.O. Technology, Inc. Inhibiteurs d'alleles alternatifs de genes utilises comme base pour agents therapeutiques contre le cancer
WO1997004087A1 (fr) * 1995-07-18 1997-02-06 Guido Krupp Ribozymes pour l'inhibition selective de l'expression de genes d'alleles du complexe majeur d'histocompatibilite(cmh), et medicaments les contenant
GB9604449D0 (en) * 1996-03-01 1996-05-01 Farrar Gwyneth J Genetic strategy ii

Also Published As

Publication number Publication date
EP0973935A2 (fr) 2000-01-26
WO1998041648A3 (fr) 1999-04-29
AU6764398A (en) 1998-10-12
WO1998041648A2 (fr) 1998-09-24

Similar Documents

Publication Publication Date Title
CA2283636A1 (fr) Genes cibles pour medicaments specifiques d'alleles
WO1998041648A9 (fr) Genes cibles pour medicaments specifiques d'alleles
Ladner et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer
Shekhar et al. Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation
US7892730B2 (en) Compositions and methods for cancer
US6200754B1 (en) Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
US20020042067A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6750013B2 (en) Methods for detection and diagnosing of breast cancer
WO2003008583A2 (fr) Nouvelles compositions et methodes relatives au cancer
US20040072154A1 (en) Novel compositions and methods for cancer
US7820447B2 (en) Compositions and methods for cancer
AU2009202600A1 (en) Novel compositions and methods for cancer
JP4538316B2 (ja) 抗オキサリプラチン耐性剤
US20100216713A1 (en) Novel compositions and methods in cancer associated with altered expression of prlr
US20030118509A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20020068036A1 (en) Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US20060211015A1 (en) Novel compositions and methods for cancer
US20030108926A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20020076707A1 (en) Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US20030157544A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003071933A2 (fr) Nouvelles compositions et procedes de traitement du cancer
AU2003225826B2 (en) Novel compositions and methods in cancer associated with altered expression of MCM3AP
US20030198951A1 (en) Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20030044803A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
WO2003027295A2 (fr) Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued